A phase 1, open-label study to evaluate the safety, tolerability, and immunogenicity of the Leish-111f + MPL-SE vaccine [leishmaniasis vaccine] in Montenegro skin-test-positive healthy adults
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2005
At a glance
- Drugs LEISH-F3 peptide vaccine (Primary) ; Monophosphoryl lipid A (Primary)
- Indications Leishmaniasis
- Focus Adverse reactions; Pharmacodynamics
- 19 Dec 2005 New trial record.